Where is OZMOSI located?

OZMOSI is headquartered in United States.

How many employees does OZMOSI have?

As of Jul 01, 2024, the latest employee count at OZMOSI is 10.

Is OZMOSI a funded company?

OZMOSI is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does OZMOSI rank among its competitors?

OZMOSI ranks 231st amongst 753 active competitors, of which 42 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Shenshi Technology, which secured $114M in Dec, 2025.

Who are the top competitors of OZMOSI?

OZMOSI's top competitors include Pharmaron, Pfizer and Boehringer Ingelheim. Among them, Shenshi Technology secured the most recent funding round in December, 2025.

OZMOSI - 2026 Company Profile, Team & Competitors

Company Details

Website: www.ozmosi.com/
Social

Key Metrics

Founded Year

2013

Location

United States

Stage

Unfunded

Ranked

231^st among 753 active competitors

Employee Count

10 as on Jul 01, 2024

Similar Companies

Pharmaron & 812 more

View OZMOSI's full profile

OZMOSI has not raised any funding rounds yet.

The founders of OZMOSI is Beau Bush.

Here are the details of OZMOSI's key team members:

Beau Bush: Founder & President of OZMOSI and founder of 1 other company.

View details of OZMOSI's Founder profiles and Board Members

OZMOSI's employee count trend

OZMOSI has 10 employees as of Jul 24. Here is OZMOSI's employee count trend over the years:

Uncover OZMOSI's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OZMOSI include Pharmaron, Pfizer and Boehringer Ingelheim. Here is the list of Top 10 competitors of OZMOSI, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pharmaron 2003, Beijing (China), Public	Suite of drug discovery and development services for small molecules	$320M	Gl-investment, Legend Capital & 11 others	76/100
2nd	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Black Capital Investments, Berkshire Hathaway ... & 16 others	73/100
3rd	Boehringer Ingelheim 1885, Ingelheim am Rhein (Germany), Funding Raised	Provider of generic drugs and clinical research services	-	Amgen Business Development, Sanderling Ventures ... & 1 others	64/100
4th	Lonza 1897, Basel (Switzerland), Acquired	Provider of CDMO services to pharma, biotech, and specialty ingredient markets	-	Defense.gov, EDBI & 4 others	59/100
5th	Tyra 2018, Carlsbad (United States), Public	Developer of cancer resistance therapies	$156M	Boxer Capital, RA Capital Management & 6 others	59/100
6th	LabConnect 2002, Johnson City (United States), Series A	Provider of laboratory testing, clinical ttrial research, and biopharma functional services	$29.2M	Broadoak Capital Partners, ABS Capital & 5 others	58/100
7th	Clearsynth 2009, Mumbai (India), Series A	CDMO focused on manufacturing of pharmaceutical small molecules and analytical research services	$4.81M	SIDBI Venture Capital, Tulip Diagnostics & 7 others	57/100
8th	Shenshi Technology 2019, Beijing (China), Series C	Developer of AI-driven platform and tools for scientific research and development	$255M	Source Code Capital, Shenzhen Hubble Technology Investment Partnership ... & 22 others	55/100
9th	Matchpoint Therapeutics 2021, Cambridge (United States), Series A	Provider of small molecular medicine development and analytics services	$100M	Access Industries, Sanofi Ventures & 4 others	55/100
10th	Evergreen Theragnostics 2019, Jersey City (United States), Acquired	Provider of radiopharmaceuticals manufacturing and regulatory services	$75.9M	Petrichor, Novacapital & 4 others	52/100
231st	OZMOSI 2013, United States, Unfunded	Provider of clinical trial data and consulting services	-	-	22/100